NCT07055477View on ClinicalTrials.gov

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

June 1, 2044

Study Completion Date

June 1, 2044

Conditions
Relapsed and/or Refractory Mature T Cell MalignancyPeripheral T-Cell LymphomaAngioimmunoblastic T-cell LymphomaAnaplastic Large Cell LymphomaHepatosplenic T-cell LymphomaMonomorphic Epithelialtropic Intestinal LymphomaEnteropathy Associated T-cell LymphomaCutaneous T-Cell LymphomaMycosis FungoidesSubacute Panniculitis-like T-cell Lymphoma
Interventions
DRUG

Cyclophosphamide

Days -5 to -3: Cyclophosphamide 300 mg/m\^2 x 3 days

DRUG

Fludarabine

Days -5 to -3: Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 3 days

BIOLOGICAL

Autologous CCR4 CAR T cells

Day 0: Cells will be infused intravenously (IV) over 10-30 minutes

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH